Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00573131 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
A Phase 2 study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT00573131 is a Phase 2 study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 137 participants.
The verdict
NCT00573131, a Phase 2 study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time. The gel will disappear in 4 to 6 weeks as it releases the paclitaxel. The protocol is directed towards evaluating the efficacy and safety of paclitaxel delivered as a local, intralesional treatment when used in combination with chemotherapy (cisplatin and 5-FU) and radiation therapy before surgery.
Interventions
- DRUG 5-FU
- DRUG cisplatin
- RADIATION radiation therapy
- DRUG OncoGel (Paclitaxel gel)
- PROCEDURE esophageal resection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2008-01 |
| Est. Completion | 2010-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00573131
The ClinicalTrials.gov registry entry for NCT00573131 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 5-FU is the first listed.
NCT00573131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00573131 about?
NCT00573131 is a clinical study titled "Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer". OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time. The gel will disappear in 4 to 6 weeks as it releases the paclitaxel. The protocol is directed towards e...
What is the current status of trial NCT00573131?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2008-01. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00573131?
The interventions under investigation include: 5-FU (DRUG), cisplatin (DRUG), radiation therapy (RADIATION), OncoGel (Paclitaxel gel) (DRUG), esophageal resection (PROCEDURE).
Who is sponsoring clinical trial NCT00573131?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.